- Citado por SciELO
- Citado por Google
- Similares en SciELO
- Similares en Google
Revista médica de Chile
versión impresa ISSN 0034-9887
LUGO-BARUQUI, Alejandro; BAUTISTA LOPEZ, Carlos Alfredo y ARMENDARIZ-BORUNDA, Juan. Novel treatments for hepatitis C viral infection and the hepatic fibrosis. Rev. méd. Chile [online]. 2009, vol.137, n.2, pp.280-288. ISSN 0034-9887. http://dx.doi.org/10.4067/S0034-98872009000200015.
Hepatitis C virus (HCV) infection represents a global health problem due to its evolution to hepatic cirrhosis and hepatocellular carcinoma. The viral pathogenesis and infectious processes are not yet fully understood. The development of natural viral resistance towards the host immune system represents a mayor challenge for the design of alternative therapeutic interventions and development of viral vaccines. The molecular mechanisms of hepatic fibrosis are well described. New alternatives for the treatment of patients with HCV infection and hepatic cirrhosis are under intensive research. New drugs such as viral protease inhibitors and assembly inhibitors, as well as immune modulators have been studied in clinical trials. Additional alternatives include antifibrotic drugs, which reverse the hepatic cellular damage caused by HCV infection. This review makes reference to viral infective mechanisms, molecular pathways of liver fibrosis and overviews conventional and new treatments for HCV infection and liver fibrosis.
Palabras clave : Cirrhosis; Fibrosis; Hepacivirus; Hepatitis C; Chroni.